There's a Blood Battle Raging Between Europe's Drug Giants

Updated on
  • Roche’s experimental hemophilia treatment is in final testing
  • NovoSeven, a $1.5 billion drug, has no direct competitor

Novo Nordisk A/S, already reeling from pricing pressure in its diabetes business, is now feeling the heat in the $8 billion market for treating hemophilia, a rare bleeding disorder.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.